Jump to content

Olopatadine

From Wikipedia, the free encyclopedia

Olopatadine
Clinical data
Trade namesPatanol, Pataday, Opatanol
AHFS/Drugs.comMonograph
MedlinePlusa602025
License data
Pregnancy
category
  • AU: B1
Routes of
administration		Eye drops, nasal spray
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only / OTC[1]
  • EU: Rx-only
Pharmacokinetic data
Elimination half-life3 hours
Identifiers
  • {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-
    dihydrodibenzo[b,e]oxepin-2-yl}acetic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H23NO3
Molar mass337.419 g·mol−1
3D model (JSmol)
  • O=C(O)Cc2ccc1OCc3c(C(\c1c2)=C\CCN(C)C)cccc3
  • InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8- checkY
  • Key:JBIMVDZLSHOPLA-LSCVHKIXSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Olopatadine, sold under the brand name Patanol among others, is an antihistamine medication used to decrease the symptoms of allergic conjunctivitis and allergic rhinitis (hay fever).[2] It is used as eye drops or as a nasal spray.[2] The eye drops generally result in an improvement within half an hour.[2]

Common side effects include headache, sore throat, eye discomfort, or changes in perception of taste.[3][2] More significant side effects may include sleepiness.[2] It is unclear if use during pregnancy or breastfeeding is safe.[4] It is an antihistamine and mast cell stabilizer.[5][2]

Olopatadine was patented in 1986 and came into medical use in 1997.[6] It is available as a generic medication.[2] In 2022, it was the 250th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[7][8]

Medical uses

[edit]

Olopatadine is an active ingredient in eye drops designed to alleviate allergic conjunctivitis, a condition characterized by itchy, red, and watery eyes. It is intended to serve as a superior alternative to eye drops that contain corticosteroids. By utilizing olopatadine, the goal is to minimize the side effects associated with corticosteroids. These side effects include elevated intraocular pressure, which can lead to glaucoma, and an increased susceptibility to infections.[9]

In nasal sprays, olopatadine is used either as a standalone active ingredient, or in a combination with mometasone, a corticosteroid. A fixed-dose combination of olopatadine hydrochloride 665 μg and mometasone furoate 25 μg is called "GSP301".[10][11][12]

Side effects

[edit]

Known side effects for olopatadine eye drops include headache, eye burning and/or stinging, blurred vision, dry eyes, foreign body sensation, hyperemia, keratitis, eyelid edema, pruritus, asthenia, sore throat (pharyngitis), rhinitis, sinusitis, taste perversion, and vomiting.[13]

Olopatadine nasal spray may cause side effects such as nosebleeds, painful nasal sores, fever, urinary discomfort, nasal congestion, cough, throat irritation, a bitter taste, drowsiness, headaches, rashes, and repeated instances of painful urination.[14][15]

Chemistry

[edit]

Synthesis

[edit]
Olopatadine synthesis:[16]

Pharmacology

[edit]

Pharmacodynamics

[edit]

Olopatadine acts as a selective antagonist of the histamine H1 receptor, thus stabilizing mast cells and inhibiting histamine release.[17]

History

[edit]

Olopatadine was patented in 1986 by Kyowa Hakko Kogyo and came into medical use in 1997.[6]

In the United States, Pataday Twice Daily Relief was first approved by the FDA in 1996, under the name Patanol as a prescription drug and was indicated for the treatment of the signs and symptoms of allergic conjunctivitis (referring to ocular redness and itching due to allergies).[1] Pataday – now Pataday Once Daily Relief – was first approved by the FDA in 2004, as a prescription drug and was indicated for the treatment of ocular itching associated with allergic conjunctivitis.[1] These drugs are mast cell stabilizers, which work by preventing the release of histamine and therefore prevent or control allergic disorders.[1]

In February 2020, Pataday Twice Daily Relief and Pataday Once Daily Relief were switched to be over-the-counter drugs in the United States when the FDA granted the approvals of the nonprescription products to Alcon.[1]

Society and culture

[edit]

Brand names

[edit]
A package of generic formulation of olopatadine eye drops sold under the brand name Pallada

Brand names include Pallada, Pazeo, Pataday, Patanol S, Patanol, Opatanol, Olopat, Patanase.[18][19] It is also available as an oral tablet in Japan under the tradename Allelock, manufactured by Kyowa Hakko Kogyo.[20]

References

[edit]
  1. ^ a b c d e "FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process". U.S. Food and Drug Administration (FDA). 14 February 2020. Archived from the original on 15 February 2020. Retrieved 14 February 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  2. ^ a b c d e f g "Olopatadine Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 27 March 2019. Retrieved 26 March 2019.
  3. ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1126. ISBN 9780857113382.
  4. ^ "Olopatadine ophthalmic Use During Pregnancy". Drugs.com. Archived from the original on 26 March 2019. Retrieved 26 March 2019.
  5. ^ Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A (June 2015). "Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis" (PDF). The Cochrane Database of Systematic Reviews. 2015 (6): CD009566. doi:10.1002/14651858.CD009566.pub2. hdl:2164/6048. PMC 10616535. PMID 26028608. Archived from the original on 28 August 2021. Retrieved 24 September 2019.
  6. ^ a b Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 549. ISBN 9783527607495. Archived from the original on 10 January 2023. Retrieved 20 September 2020.
  7. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  8. ^ "Olopatadine Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  9. ^ Zi Y, Deng Y, Ji M, Qin Y, Nong L, Liu Z, et al. (2020). "The effectiveness of olopatadine hydrochloride eye drops for allergic conjunctivitis: Protocol for a systematic review". Medicine. 99 (7): e18618. doi:10.1097/MD.0000000000018618. PMC 7035116. PMID 32049778.
  10. ^ Prenner BM, Amar NJ, Hampel FC, Caracta CF, Wu W (2022). "Efficacy and safety of GSP301 nasal spray in children aged 6 to 11 years with seasonal allergic rhinitis". Annals of Allergy, Asthma & Immunology. 129 (5): 618–626.e2. doi:10.1016/j.anai.2022.07.029. PMID 35926824.
  11. ^ Chen R, Zheng D, Zhang Y, Sima G (2022). "Efficacy and safety of twice-daily olopatadine–mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: A systematic review and meta-analysis". European Archives of Oto-Rhino-Laryngology. 279 (4): 1691–1699. doi:10.1007/s00405-021-07085-w. PMID 34591150.
  12. ^ Segall N, Lumry W, Prenner B, Caracta C, Tantry S (2018). "Long-Term Safety and Efficacy of Olopatadine/Mometasone Combination Nasal Spray in Patients with Perennial Allergic Rhinitis". Annals of Allergy, Asthma & Immunology. 121 (5): S60. doi:10.1016/j.anai.2018.09.199.
  13. ^ "Olopatadine ophthalmic Side Effects: Common, Severe, Long Term". Archived from the original on 19 June 2024. Retrieved 14 July 2024.
  14. ^ "Olopatadine nasal Uses, Side Effects & Warnings".
  15. ^ Klimek L, Klimek F, Bergmann C, Hagemann J, Cuevas M, Becker S (2024). "Efficacy and safety of the combination nasal spray olopatadine hydrochloride-mometasone furoate in the treatment of allergic rhinitis". Allergo Journal International. 33: 9–19. doi:10.1007/s40629-023-00282-5.
  16. ^ Ueno K, Kubo S, Tagawa H, Yoshioka T, Tsukada W (July 1976). "6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity". Journal of Medicinal Chemistry. 19 (7): 941–6. doi:10.1021/jm00229a017. PMID 940112.
  17. ^ Gonzalez-Estrada A, Reddy K, Dimov V, Eidelman F (August 2017). "Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis". Expert Opinion on Pharmacotherapy. 18 (11): 1137–1143. doi:10.1080/14656566.2017.1346085. PMID 28656804.
  18. ^ "Olopatadine (Ophthalmic): Drug information".
  19. ^ "Drugs.com, Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms". Archived from the original on 17 April 2009. Retrieved 23 January 2018.
  20. ^ Kyowa Hakko Kogyo Co., Ltd. (2007). "Allelock Tablets 2.5 & Allelock Tablets 5 (English)" (PDF). Archived from the original (PDF) on 22 July 2011. Retrieved 10 August 2008.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Olopatadine&oldid=1260709367"